Lyndsay Harris

Dana-Farber Cancer Institute

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

1 more share only the name and are not shown

Trial papers in breast cancer

PubMed author-name match

Trials

Studies that name Lyndsay Harris as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:12 UTC. Open this list on ClinicalTrials.gov

Ph1
NCT00039455 · Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
National Cancer Institute (NCI) · terminated · HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

Targeted Combinations for Her2- Positive Breast Cancer Biology
P50CA089393 · NCI · DANA-FARBER CANCER INST · fiscal years 2005 to 2009 · $137,947 awarded in 2009
Grant number is on one of their registry trials
ERBB2/P53 AND TAXANE CHEMOTHERAPY FOR BREAST CANCER
R01CA086774 · NCI · DANA-FARBER CANCER INST · fiscal years 1999 to 2000 · $206,502 awarded in 2000
Same name and institution; not confirmed by an ID

Most cited trial papers

Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:12 UTC. The ranking covers the 200 most relevant of 48 PubMed records, and a shared surname and initials can bring in a namesake. All 48 on PubMed